Candy giant CEO joins weight loss drug giant Novo Nordisk.

On March 26th local time, Novo Nordisk announced at its annual shareholders' meeting the appointment of Mars Inc. CEO Paul Weilach as a board observer. Novo Nordisk stated that the weight loss drug market is becoming increasingly consumer-driven, and the company is studying consumer behavior.